Close Menu

NEW YORK (360Dx) – San Diego-based TearLab announced yesterday that its next-generation, multiplex diagnostics platform for human tear samples has received CE marking as an in vitro diagnostic medical device.

The CE mark also covers an assay for response to dry eye disease therapy, which measures both osmolarity, a measure of solute concentration, and an inflammation biomarker.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.